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Introduction: Elafin is an endogenous serine protease inhibitor. The majority of breast cancer cell lines lack elafin
expression compared to human mammary epithelial cells. In this study, we hypothesized that elafin is
downregulated during breast and ovarian tumorigenesis.
Methods: We examined elafin expression by immunohistochemistry (IHC) in specimens of normal breast tissue
(n = 24), ductal carcinoma in situ (DCIS) (n = 54), and invasive breast cancer (n = 793). IHC analysis of elafin
expression was also performed in normal fallopian tube tissue (n = 20), ovarian cystadenomas (n = 9), borderline
ovarian tumors (n = 21), and invasive ovarian carcinomas (n = 216). To understand the significance of elafin in luminal
breast cancer cell lines, wild-type or M25G elafin (lacking the protease inhibitory function) were exogenously expressed
in MCF-7 and T47D cells.
Results: Elafin expression was downregulated in 24% of DCIS and 83% of invasive breast tumors when compared to
elafin expression in the normal mammary epithelium. However, the presence of elafin-positive cells in invasive breast
tumors, even at low frequency, correlated with poor recurrence-free survival (RFS), reduced overall survival (OS), and
clinicopathological markers of aggressive tumor behavior. Elafin-positive cells were an especially strong and independent
prognostic marker of reduced RFS in IHC-defined luminal A-like tumors. Elafin was also downregulated in 33% of ovarian
cystadenomas, 43% of borderline ovarian tumors, and 86% of invasive ovarian carcinomas when compared to elafin
expression in the normal fallopian tube. In ovarian tumors, elafin-positive cells were correlated with reduced RFS, OS and
disease-specific survival (DSS) only in stage I/II patients and not in stage III/IV patients. Notably, exogenous expression of
elafin or elafin M25G in the luminal breast cancer cell lines MCF-7 and T47D significantly decreased cell proliferation in a
protease inhibitory domain-independent manner.
Conclusions: Elafin predicts poor outcome in breast and ovarian cancer patients and delineates a subset of endocrine
receptor-positive breast cancer patients susceptible to recurrence who could benefit from more aggressive intervention.
Our in vitro results suggest that elafin arrests luminal breast cancer cells, perhaps suggesting a role in tumor dormancy.Introduction
Elafin was originally characterized as an endogenous
inhibitor of the serine proteases neutrophil elastase
(NE) and proteinase 3 (PR3) [1]. Notably, elafin has also
demonstrated anti-inflammatory, immune modulatory, and
anti-microbial properties, independent of its protease
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unless otherwise stated.the majority of epithelial tissues express elafin at relatively
low levels, however elafin is highly upregulated in response
to proinflammatory cytokines, such as interleukin 1 beta
(IL-1β) and tumor necrosis factor alpha (TNF-α) [3]. In
this context, elafin is an important component of the
epithelial anti-protease shield. Elafin downregulation
is associated with the pathogenesis of several inflammatory
conditions, including acute respiratory distress syndrome
and inflammatory bowel disease [4,5]. In animal models of
inflammatory disease, elafin overexpression preserved
tissue integrity and function [6] providing evidence thatThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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activity is critical to the maintenance of tissue homeostasis.
Elafin was not detected at the mRNA level in breast
tumor-derived cell lines, compared to elafin expression
in normal human mammary epithelial cells (HMECs) [7,8].
Our laboratory previously reported that the transcription
factor C/EBP β was required for elafin expression in
HMECs. C/EBP β was frequently deregulated during
breast tumorigenesis through accumulation of a truncated
dominant-negative isoform [8]. We also found that ectopic
expression of elafin-induced apoptosis in Rb-negative and
growth arrest in Rb-positive breast cancer cell lines [9,10].
Collectively, the in vitro evidence suggests that elafin has
tumor-suppressive properties in the context of breast
cancer. Based on these observations, we hypothesized
that elafin is expressed in normal mammary and fallopian
tube epithelia, but downregulated during breast and ovarian
tumorigenesis. As an important endogenous inhibitor of
NE, elafin downregulation could enhance NE activity and
its protumorigenic capacity.
In this study, we set out to comprehensively examine
the expression of elafin protein in the context of breast
and ovarian tumorigenesis using patient-derived tissue
specimens. To this end, we examined elafin expression by
immunohistochemistry (IHC) in normal and malignant
breast and ovarian tissues. Compared to elafin ex-
pression in the normal mammary epithelium, we ob-
served that elafin was largely downregulated (that is
switched off) during breast tumorigenesis. A complemen-
tary IHC analysis revealed a similar downregulation of elafin
expression during ovarian tumorigenesis compared to elafin
expression in the epithelium of the normal fallopian tube.
However, residual elafin-positive cells were also observed,
generally at low frequency, in a subset of breast and ovarian
tumors and were associated with an aggressive tumor
phenotype and poor outcome. Significantly, the presence of
residual elafin-positive cells was a strong, independent
prognostic marker of poor recurrence-free survival
(RFS) specifically in IHC-defined luminal A subtype tumors
(that is estrogen receptor-positive (ER+)/progesterone
receptor-positive (PR+)/Ki67low), the largest and most
diverse breast cancer subtype and the greatest contributor
to overall breast cancer mortality [11]. This correlation was
also observed in stage I/II (but not stage III/IV) ovarian
cancer cohorts. Lastly, we show that exogenous expression
of elafin significantly decreased cell proliferation in luminal
breast cancer cell lines independent of its protease
inhibitory function, suggesting a role for elafin in tumor
dormancy and recurrent disease.
Methods
Patient samples
Tissue microarrays (TMAs) contained specimens of breast
tumors from patients with pathologic stage I or II breastcancer diagnosed between 1985 and 2000 at the University
of Texas MD Anderson Cancer Center (UTMDACC)
[12]. Overall, 793 patient tumor samples were scored for
elafin expression, the TMAs also contained normal breast
tissue from reduction mammoplasty and pure ductal
carcinoma in situ (DCIS) specimens collected from
patients at UTMDACC. Invasive breast tumors were
previously subclassified using the IHC markers ER,
PR, human epidermal growth factor receptor 2
(HER2), and Ki67 (cutoff = 20%) into luminal A-like
(ER+/PR+/Ki67low), luminal B-like (ER+/PR+/Ki67high)
HER-2-positive, and triple-receptor negative breast
cancer (TNBC; approximating the basal-like intrinsic
subtype) [12]. A separate set of TMAs for elafin staining
contained ovarian carcinoma samples from patients
diagnosed between 1990 and 2007 at UTMDACC
[13]. Overall, 213 patient tumor samples were scored for
elafin expression, the TMAs also contained samples of
ovarian cystadenoma, borderline tumors, and normal
fallopian tube tissue obtained from patients at UTMDACC.
The Institutional Review Board (IRB) at UTMDACC
approved the use of patient-derived specimens and data.
Specifically, IRB LAB11-0418 entitled ‘Prognostic factors in
ovarian cancer’ (Study Chair: JL); IRB LAB04-0796 entitled
‘Biological markers of breast carcinoma’ (Study Chair: CA)
and IRB LAB00-222 entitled ‘Cyclin E expression in breast
cancer’ (Study Chair: KKH). All necessary consents from all
patients involved in this study were obtained according to
each aforementioned IRB protocol.
Immunohistochemistry
For elafin staining, deparaffinized TMA slides were
subjected to heat-induced antigen retrieval using citrate
buffer (Vector Laboratories, Burlingame, CA, USA).
Endogenous peroxidases were quenched in 3% H2O2, and
the sections were blocked with 1.5% normal goat serum
and incubated overnight at 4°C with primary antibody: ela-
fin (clone TRAB/2 F; HyCult Biotech, Plymouth Meeting,
PA, USA) diluted 1:200. We also tested Hycult Biotech,
Clone: TRAB/2O (targeting the N-terminal transglutimase-
linking domain of full-length elafin), however, TRAB2F
(targeting the 57 C-terminal amino acids of fully processed
elafin) appears to be more specific to elafin than TRAB/2O
based on western blot analysis results (Additional file 1:
Figure S1A). Slides were developed using the VECTASTAIN
Elite ABC Kit followed by DAB substrate (Vector
Laboratories) and counterstained with hematoxylin
(Dako Agilent Technologies, Santa Clara, CA, USA).
For quantification of elafin expression we employed
a scoring system modified from Allred et al. 1998, which
consists of a final elafin IHC score (0 to 8) that is the sum
of an intensity score (0 = negative, 1 = low, 2 =medium,
and 3 = high) and a frequency score (0 = 0%, 1 = <1%, 2 = 1
to 10%, 3 = 10 to 33%, 4 = 33 to 66%, and 5 = 66 to 100%)
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elafin but were blinded to patient outcomes. For a detailed
protocol, see supplemental information. For statistical
analysis, we utilized two cutoffs to separately classify
patient-derived tissue specimens based on elafin expression.
First, we scored elafin expression in normal tissue (that is
normal mammary gland and fallopian tube) and chose a
threshold encompassing the range of elafin expression
observed in normal tissue (the cutoff was set at the
minimum value in the range). All specimens of normal
breast epithelium were scored a six, therefore, we defined
elafin downregulation as any specimen scoring less than
six. Analysis of elafin expression in the normal fallopian
tube revealed that the majority of specimens scored
between four and six, therefore we defined elafin
downregulation as any specimen scoring less than four.
This cutoff was used to delineate specimens expressing
normal levels of elafin and specimens demonstrating elafin
downregulation comparatively. Second, we considered the
prognostic significance of any elafin expression (that is a
score greater than 0) in the invasive tumor cohorts. Using
this cutoff, we compared elafin-positive to elafin-negative
tumors.
Statistical analysis
Fisher’s exact test or Kruskal-Wallis rank test were used
to compare patient and tumor characteristics, performed
using SPSS (version 12) (SPSS Inc, Chicago, IL, USA).
For Kaplan-Meier survival analysis: RFS was calculated
as the number of years between the date of diagnosis
and the first local recurrence. For the analysis, we
censored patients who were lost to follow-up or did
not suffer a recurrence. Disease-specific survival (DSS)
was calculated as the number of years between the date of
diagnosis and date of death due to disease. Patients who
died from causes other than the disease (that is ovarian
cancer) were censored. We calculated the overall survival
(OS) as the number of years between the date of diagnosis,
the date of death, or last follow-up, whichever came first
(Prism version 6.0b, GraphPad Software, San Diego, CA,
USA). Statistical significance was determined using the
rank-sum test. We performed multivariate Cox proportional
hazards for RFS using Stata SE (version 10.0) (StataCorp,
College Station, TX, USA). Statistical tests were two-tailed
and statistical significance was set at P <0.05.
Cell lines and culture conditions
All tumor cells were obtained from American Type Culture
Collection (ATCC, Rockville, MD, USA) and authenticated.
Tumor cell lines were cultured in α-MEM (HyClone, GE
Healthcare Life Sciences, Logan, UT, USA) containing 10%
fetal calf serum (Atlanta Biological, Flowery Branch, GA,
USA) [9], unless dissimilar culture conditions were speci-
fied by ATCC. Immortalized 76NE6 HMECs were obtainedfrom Dr. V. Band [15] and cultured in DFCI-1, as
previously described [16]. Cell lines were maintained
in a humidified tissue culture incubator at 37°C and
6.5% CO2. Lentiviral vectors containing green fluores-
cent protein (GFP), elafin, or elafin M25G were gen-
erated and packaged in HEK-293 T cells using the
pCMV deltaR8.2 and pMD2.G vectors produced by
the Didier Trono laboratory and made available through
the Addgene repository. Target cells were infected with
the virus-containing medium in the presence of 8 μg/mL
polybrene. The cells were selected in 20 μg/ml blastici-
din. Details of plasmid construction can be found in
Additional file 2.
qPCR analysis
qPCR was performed using a protocol adapted from
[17]. RNA was extracted from 2 × 106 cells using the
RNAeasy kit (Qiagen, Valencia, CA) and subjected to
on-column DNase I (NEB) digestion. The RNA was re-
verse transcribed using the First Strand cDNA synthesis
kit (Roche, Indianapolis, IN). The resultant cDNA was
subjected to qPCR using SYBR Green PCR Master Mix
(Applied Biosystems, Waltham, MA, USA) on an Applied
Biosystems 7500 real-time PCR system. Fold difference
was calculated using the ΔΔCT method, where GAPDH








Nunc-Immuno MaxiSorp U96 plates (Thermo Fisher
Scientific, Waltham, MA, USA) were coated with elafin
polyclonal antibody (Hycult Biotech) at a concentration of
10 μg/mL diluted in 0.1 M sodium bicarbonate overnight
at 4°C. The plate was blocked in 1 μg/mL bovine serum
albumin (BSA) (Sigma-Aldrich, St Louis, MO, USA) in
phosphate-buffered saline (PBS) (4 hours) prior to incuba-
tion with 200 μL of conditioned medium or serially
diluted recombinant elafin (Calbiochem, Merck Millipore,
Billerica, MA, USA) as a control. A mouse monoclonal
antibody against elafin (clone: TRAB/2O, HyCult Biotech)
was utilized at a concentration of 50 ng/mL for elafin
detection. The secondary antibody used was 50 ng/mL
goat anti-mouse immunoglobulin G (IgG) horseradish
peroxidase (HRP) conjugated (Thermo Fisher Scientific).
The enzyme-linked immunosorbent assay (ELISA) was
developed using 1-Step Ultra TMB (Thermo Fisher
Scientific), the reaction was quenched with 2 M phosphoric
acid, and absorbance was measured at 450 nM.
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Cells were harvested using trypsin, lysed via sonication
in the presence of protease/phosphatase inhibitors, and
subjected to western blot analysis as previously described
[9]. Mouse monoclonal antibodies to elafin (clone: TRAB/
2 F, HyCult Biotech) and actin (Chemicon, Temecula, CA,
USA) were utilized in this analysis. Cells were plated at a
concentration of 5,000 cells per well in a 24-well plate. At
each time point examined, the cells were harvested via
trypsinization, and cell number was determined using
the trypan blue (Fluka) exclusion test (Sigma-Aldrich)
and a standard hemocytometer. Statistical significance
was evaluated by t test, (Prism version 6.0b, GraphPad
Software).
Results
Elafin is downregulated in breast tumor specimens
compared to the normal mammary epithelium
We utilized patient-derived tissue specimens to test the
hypothesis that elafin is expressed in the normal mammary
epithelium, but downregulated during breast tumorigenesis.
Using the highly specific monoclonal antibody against elafin
(Hycult Biotech, clone: TRAB/2 F) (Additional file 1:
Figure S1A and Figure S1B ) [18], we subjected TMAs
containing sections of normal breast tissue from reduction
mammoplasty (n = 24), DCIS (n = 54), and invasive breast
carcinoma (n = 793) to IHC analysis (Figure 1). Despite a
secretion signal near the N-terminus of the elafin peptide
sequence [19], elafin expression is intracellularly localized
when evaluated by IHC (Figure 1A). In order to quantify
the expression of intracellular elafin, we employed a scoring
system modified from Allred et al. 1998, which consists
of a final elafin IHC score (0 to 8) that is the sum
of an intensity score (0 to 3) and a frequency score
(0 to 5) (Additional file 1: Figure S1C and Figure S1D) [14].
Quantification revealed that elafin is consistently expressed
at high levels in the epithelium of the normal mammary
gland compared to cases of DCIS and invasive breast carcin-
oma. Based on elafin expression in the normal breast epithe-
lium, we used the elafin IHC score of 6 as a cutoff to define
elafin downregulation, such that a score of 6 to 8 is classified
as positive and a score 0 to 5 is classified as negative
(Figure 1B). Using these classifications, elafin expression is
comparable to normal breast tissue in 76% of DCIS cases,
but only 17% of invasive breast carcinoma cases (Figure 1C).
Overall, these results highlight the downregulation
(that is switching off ) of intracellular elafin expression
during breast tumorigenesis when compared to elafin
expression in the normal breast epithelium.
Elafin is downregulated in ovarian tumor specimens
compared to the normal fallopian tube epithelium
We next analyzed elafin expression in ovarian cancer.
TMAs containing sections of normal fallopian tube (n = 20),ovarian cystadenomas (n = 9), borderline ovarian tumors
(tumors with low malignant potential) (n = 21), and invasive
ovarian carcinoma (n = 216) were subjected to IHC ana-
lysis of elafin expression (Figure 2). Elafin was generally
expressed in the normal fallopian tube epithelium
(Figure 2A), consistent with previously published studies
[20,21]. However, greater variability was observed in the
normal fallopian tube (Figure 2B) compared to normal
breast tissue (Figure 1B). We used the elafin IHC score of
4, encompassing elafin expression in the majority of
normal cases, as a cutoff to define elafin downregulation,
such that a score of 4 to 8 is classified as positive and a
score 0 to 3 is classified as negative (Figure 2B). Based on
this analysis, elafin expression is comparable to the normal
fallopian tube in 67% of ovarian cystadenomas and 57% of
borderline ovarian tumors, but only 14% of invasive
ovarian carcinomas (Figure 2C). These results demon-
strate that, similar to the results from breast cancer
patients (Figure 1), elafin is downregulated during ovarian
tumorigenesis in comparison to elafin expression in the
epithelium of the normal fallopian tube.
Elafin-positive tumor cells are prognostic of poor RFS in
breast cancer
We found that elafin was downregulated in the majority
of breast and ovarian tumors compared to the normal
mammary epithelium or normal fallopian tube. However,
only 40% of breast tumors were completely elafin
negative, while the remaining 60% of tumors contained
elafin-positive cells (Figure 3A), generally at low frequency
(Figure 3B). We next investigated the clinical significance
of these elafin-positive cells in both the breast and ovarian
tumor cohorts.
We compared the clinicopathological characteristics
of breast cancer patients whose tumors lacked any
elafin-positive cells (IHC score = 0) to those whose tumors
contained elafin-positive cells (IHC score >0). Univariate
analysis revealed that the presence of elafin-positive tumor
cells was significantly associated with younger age, higher
tumor stage, higher tumor grade, and tumor recurrence
(Table 1A). Kaplan-Meier analysis revealed that tumors
with elafin-positive cells have significantly (log rank test)
reduced RFS (Figure 3C) and decreased OS (Figure 3D).
In multivariate Cox proportional hazards analysis,
elafin-positive cells were independently prognostic of poor
breast cancer RFS with a hazard ratio (HR) of 1.94
(P <0.0001) (Table 1B).
Next, we used the publically available RNA-seq dataset
from The Cancer Genome Atlas (TCGA) [22] to examine
the mRNA expression pattern of elafin in tumor tissue
from breast cancer patients. In this dataset, the luminal A,
luminal B, and HER-2 enriched tumors were characterized
by elafin downregulation (Additional file 1: Figure S2A






































































Figure 1 Elafin is downregulated in breast tumor specimens compared to the normal mammary epithelium. (A) Representative
photomicrographs of elafin immunohistochemical (IHC) staining (using the monoclonal antibody TRAB/2 F from Hycult Biotech) in normal
breast from reduction mammoplasty (i and ii), pre-invasive ductal carcinoma in situ (DCIS) (iii and iv) and invasive breast carcinoma (v and vi).
(B) Frequency distribution illustrating the percentage of cases falling into each categorical score over the range 0 to 8 for normal breast tissue,
DCIS, and invasive breast carcinoma. The dashed lines represent the cutoff used in this analysis, which was set at an elafin score of 6 based on
consistent elafin expression in the normal breast epithelium. (C) Quantification of elafin expression in the normal mammary breast, DCIS, and
invasive breast carcinoma tissue specimens: IHC-positive cases express elafin at or above the level of elafin expression in the normal breast
epithelium (elafin score 6 to 8) and negative cases represent elafin downregulation compared to normal breast epithelium (elafin score 0 to 5),
statistical significance determined by Fisher’s exact test.
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(Additional file 1: Figure S2B). Similarly, we observed
significant differences in the distribution of breast
cancer subtypes between tumors harboring and lacking
elafin-positive cells (Table 1A). Overall, luminal A-like
(ER+/PR+/Ki67low) subtype breast tumors were significantly
less likely to have elafin-positive cells compared to luminal
B (ER+/PR+/Ki67high), HER2-postive, and TNBC subtypes
(Figure 4A). We next segregated patients by tumor subtype
and repeated the Kaplan-Meier analysis. In IHC-defined
luminal A-like subtype patients, elafin-positive cells were
prognostic of a highly significant reduction in RFS com-
pared to elafin-negative tumors (Figure 4B). Elafin-positive
cells were not associated with reduced RFS in any other
tumor subtype (notably, the correlation between reduced
RFS and elafin-positive cells trended toward significance
in TNBC patients (P = 0.07)). Univariate analysis of
IHC-defined luminal A-like subtype breast cancer patientsrevealed that elafin-positive cells were associated with
higher tumor stage, higher tumor grade, and recurrence
(Table 2A). Furthermore, multivariate analysis revealed
that elafin-positive cells were independently prognostic of
RFS with a HR of 3.0 (P <0.0001) in IHC-defined luminal
A-like subtype breast cancer patients (Table 2B). These
results suggest that elafin-positive cells, even at low
frequency, were independently prognostic of reduced RFS
in breast cancer patients, particularly with IHC-defined
luminal A-like (ER+/PR+/Ki67low) subtype tumors.
Elafin-positive tumor cells are prognostic of reduced DSS
in stage I/II ovarian cancer
Elafin was downregulated in the majority of ovarian
tumors compared to the epithelium of the normal fallopian
tube (Figure 5A). Overall, 80% of ovarian tumors were
completely elafin negative and the remaining 20%







































































































































Figure 2 Elafin is downregulated in ovarian tumor specimens compared to the normal fallopian tube epithelium. (A) Representative
photomicrographs of elafin IHC staining (using the monoclonal antibody TRAB/2 F from Hycult Biotech) in normal fallopian tube (i and ii), ovarian
cystadenoma (iii), ovarian borderline tumor (iv), and invasive ovarian carcinoma (v and vi). (B) Quantification of elafin immunohistochemical (IHC)
staining: positive cases are at or above the level of elafin expression in the epithelium of the normal fallopian tube and negative cases represent
elafin downregulation compared to the epithelium of the normal fallopian tube. The dashed lines represent the cutoff used in this analysis, which
was set at an elafin score of 4 based on the range of elafin expression in the normal fallopian tube. (C) Frequency distribution illustrating the
percentage of cases, evaluated by IHC, falling into each categorical score over the range 0 to 8 for normal fallopian tube, ovarian cystadenomas,
ovarian borderline tumors, and invasive ovarian carcinoma, statistical significance determined by Fisher’s exact test.
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AFrequency TNBC Her2+ Luminal B Luminal A
0% 18.3 29.5 32.1 54.2
1-10% 45.1 44.6 40.0 28.9
10-33% 19.0 13.0 15.0 9.3
>33% 17.6 12.9 12.9 7.6
n=153 n=149 n=140 n=342
Frequency of Residual Elafin Positive Tumor Cells 
B
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Figure 3 Elafin-positive tumor cells are prognostic of poor RFS in breast cancer. (A) Representative photomicrographs of elafin
immunohistochemical (IHC) staining in invasive breast carcinoma demonstrating i and ii: negative (elafin score = 0) and iii to vi: positive
(elafin score >0) staining. (B) Frequency of elafin-positive cells in breast tumors by subtype split into the categories 0%, 1 to 10%, 10 to 33%,
and greater than 33%. (C, D) Kaplan-Meier survival analysis of elafin-positive and -negative breast cancer cases, significance calculated by
rank-sum test. (C) Recurrence-free survival (RFS) and (D) overall survival (OS).
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significance of elafin-positive tumor cells in breast
cancer patients, we next examined their significance
in ovarian cancer patients. We compared ovarian cancer
patients whose tumors lacked elafin-positive cells (IHC
score = 0) to patients whose tumors contained elafin-
positive cells (IHC score >0) (Figure 5A and B). Univariate
analysis revealed that elafin-positive tumor cells were
significantly associated with makers of aggressive
tumor behavior including, higher tumor stage, ascites,
resistance to treatment, and higher serum CA125
(Additional file 1: Table S1A). Kaplan-Meier analysis
revealed that tumors with residual elafin-positive cells
had significantly (log rank test) reduced OS and DSS
(Figure 5C). Next we separated the stage I/II and stage
II/IV ovarian cancer patients into separate cohorts
and subjected each cohort to OS, DSS and RFS analysis.
Kaplan-Meier analysis revealed that stage I/II patients with
elafin-positive cells within their tumors had significantly(log rank test) reduced DSS and OS (Figure 5C), while
stage III/IV patients were not further stratified by elafin
expression. In multivariate analysis, elafin-positive cells
were not independently prognostic of poor ovarian cancer
DSS (Additional file 1: Table S1B). Collectively, the
IHC analysis revealed that elafin was downregulated
during ovarian tumorigenesis, however, elafin-positive
cells were prognostic of poor DSS only in stage I/II
ovarian cancer patients.
Exogenous elafin has growth-suppressive properties in
luminal breast cancer cell lines normally lacking elafin
expression
Next we set out to investigate the significance of elafin
expression in luminal breast cancer. For these studies we
initially interrogated the relative elafin mRNA expression
in 48 breast cancer cell lines and two HMECs using a
microarray dataset [23]. Consistent with the previous
publications [7,8], elafin expression was downregulated
Table 1 Univariate and multivariate analysis of
elafin-positive cells in breast cancer patients








Age of diagnosis, year 0.02
Mean 55.5 53.5
Median (range) 55 (26–86) 52 (25–87)
Stage <0.0001
I 120 (38.7) 115 (24.0)
IIA 128 (41.3) 241 (50.2)
IIB 62 (20.0) 124 (25.8)
Unknown 1 2
ER <0.0001
Positive 266 (85.5) 280 (58.3)
Negative 45 (14.5) 200 (41.7)
Unknown 0 2
PR <0.0001
Positive 218 (70.1) 236 (49.2)
Negative 93 (29.9) 244 (50.8)
Unknown 0 2
HER-2 0.013
Positive 42 (13.5) 98 (20.4)
Negative 269 (86.5) 383 (79.6)
Unknown 0 1
Grade <0.0001
I 41 (14.2) 31 (6.8)
II 186 (64.6) 197 (43.5)
III 61 (21.2) 225 (49.7)
Unknown 23 29
Tumor subtype <0.0001
Luminal A 185 (61.9) 158 (33.1)
Luminal B 45 (15.1) 94 (19.8)
Her2 positive 42 (14.0) 98 (20.7)
Triple negative 27 (9.0) 125 (26.4)
Unknown 12 7
Recurrence <0.0001
No 250 (80.9) 298 (62.3)
Yes 59 (19.1) 180 (37.7)
Unknown 2 4
B: Multivariate Cox proportional hazards analysis of
clinicopathologic variables’ influence on breast cancer RFS in
whole cohort (n = 793)
Factor HR Se P 95% CI
Stage
I referent
IIA 1.67 0.31 0.005 1.17-2.39
Table 1 Univariate and multivariate analysis of
elafin-positive cells in breast cancer patients (Continued)
IIB 2.41 0.47 <0.0001 1.65-3.52
Age 0.98 0.01 <0.0001 0.97-0.99
Elafin positive 1.94 0.3 <0.0001 1.44-2.62
(A) The association between common clinicopathological characteristics and
the presence or absence of elafin-positive cells in breast tumor specimens was
examined. Significance was determined by Fisher’s exact test or Kruskal-Wallis
rank test. Unknowns were excluded in this analysis. (B) Multivariate Cox
proportional hazards analysis of clinicopathologic variables’ influence on RFS
in the entire cohort of breast cancer patients. CI, confidence interval; ER,
estrogen receptor; HR, hazard ratio; HER2, human epidermal growth factor
receptor 2; PR, progesterone receptor; RFS, recurrence-free survival.
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elafin expression in immortalized HMECs (MCF-10A
and MCF12A) (Figure 6A). However, in this analysis,
there was a subset of TNBC cell lines that expressed
elafin at levels comparable to HMECs (Figure 6A). We
confirmed comparable elafin expression at the mRNA
level in HMECs (76NE6) and representative TNBC cell
lines (MDA-MB-436, MDA-MB-157, MDA-MB-468) by
qPCR (Figure 6B). In this analysis, the luminal breast
cancer cell lines examined (MCF-7, T47D, ZR75-1) did
not express elafin at the mRNA level (Figure 6B). Elafin
could not be detected in tumor cell lysates from TNBC or
luminal breast cancer cell lines (data not shown). Elafin is
a secreted protein [19], therefore we examined its levels in
conditioned media by ELISA. We found that TNBC cell
lines and HMECs, which expressed elafin at the mRNA
level (Figure 6B), secreted elafin into the conditioned
media (Figure 6C). The conditioned media of luminal-like
breast cancer cell lines, which failed to express elafin
mRNA (Figure 6B), was appropriately negative for elafin
expression (Figure 6C).
To interrogate the significance of elafin expression in
luminal breast cancer cell lines we generated MCF-7 and
T47D cells expressing either wild-type elafin or elafin
M25G, bearing a mutation in the protease inhibitory
rendering it incapable of protease inhibition [24]; cells
expressing GFP were used as a control (Figure 6D). Cell
number was quantitated at 24, 48, 72, and 96 hours
revealing a decrease in cell proliferation, evidenced by an
increase in cell-doubling time, in elafin and elafin M25G
expressing MCF-7 and T47D cells compared to the
GFP-expressing controls (Figure 6D). In this analysis,
MCF-7 control cells had a doubling time of 22.4 hours,
while elafin-overexpressing cells had a doubling time of
26.9 hours and elafin M25G cells had a doubling time of
30 hours. Differences in doubling time were even more
pronounced in T47D cells, compare 24.3 hours for the
controls, to 36.9 and 32.1 for elafin and elafin-M25G cells
respectively (Figure 6D). These in vitro analyses suggest
that elafin plays a role in growth suppression and may be
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Figure 4 Elafin-positive tumor cells are prognostic of poor RFS in luminal A-like (ER+/PR+/Ki67low) breast cancer. (A) The proportion of
tumors positive (elafin score > 0) and negative (elafin score = 0) for elafin-positive cells, separated by breast cancer subtype. Statistical significance
determined by Fisher’s exact test. (B) Patients were separated by breast cancer subtype, luminal A-like, luminal B, triple receptor-negative breast
cancer (TNBC), and human epidermal growth factor receptor 2 (HER2)-postive. Kaplan-Meier survival analysis of recurrence-free survival (RFS) in
elafin-positive (elafin score > 0) and negative (elafin score = 0) breast cancer cases. Significance calculated by rank-sum test.
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In this study, we made two important observations
regarding the expression of elafin in breast and ovarian
cancer. First, elafin was downregulated in a large propor-
tion of tumor specimens compared to matched normal
tissues, suggesting that elafin possesses tumor-suppressive
properties. Second, we observed that the presence of
elafin-positive cells, even at low frequency, correlated
with poor outcome and clinicopathological markers of
aggressive tumor behavior.Our IHC analysis revealed that elafin was consistently
expressed by the normal mammary epithelium, but
downregulated in 24% of DCIS and 83% of invasive
breast carcinoma specimens (Figure 1C). We performed
a complementary IHC analysis of elafin expression in
patient-derived specimens of ovarian tumorigenesis. A
large proportion of ovarian carcinomas originate from the
epithelium of the fallopian tube [25]. Elafin was robustly
expressed in the epithelium of the majority of normal
fallopian tube specimens examined (Figure 2), consistent
Table 2 Univariate and multivariate analysis of
elafin-positive cells in luminal A-like breast cancer patients
A: Univariate analysis of clinicopatholoigal variable in luminal A








Age at diagnosis, year 0.8
Mean 56.7 56.4
Median (range) 55 (26–84) 57 (29–87)
Stage <0.0001
I 81 (44.0) 38 (24.2)
IIA 79 (42.9) 83 (52.9)
IIB 24 (13.0) 36 (22.9)
Unknown 1 1
Grade 0.001
I 31 (18.3) 15 (10.3)
II 122 (72.2) 96 (65.7)
III 16 (9.5) 35 (24.0)
Unknown 16 12
Recurrence <0.0001
No 158 (86.3) 98 (62.4)
Yes 25 (13.7) 59(37.6)
Unknown 2 1
B: Multivariate of clinicopathologic variables’ influence on RFS
in luminal A patients (n = 343)
Factor HR Se P 95% CI
Age 0.97 0.01 <0.0001 0.95-0.98
Elafin positive 3 0.73 <0.0001 1.87-4.82
(A) The association between common clinicopathological characteristics and
the presence or absence of elafin-positive cells in luminal A-like breast tumor
specimens was examined by Fisher’s exact test or Kruskal-Wallis rank test.
Unknowns were excluded in this analysis. (B) Multivariate Cox proportional
hazards analysis of clinicopathologic variables’ influence on RFS in luminal
A-like subtype breast cancer patients only. CI, confidence interval; HR, hazard
ratio; RFS, recurrence-free survival.
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downregulated in 33% of ovarian cystadenomas, 43% of
borderline ovarian tumors, and 86% of invasive ovarian
cancer (Figure 2C). Elafin overexpression was previously
reported in serous ovarian tumors [26], however, the
threshold (6% elafin-positive cells) used to define elafin
overexpression was not calibrated to elafin expression in
normal tissue. Elafin downregulation during breast and
ovarian tumorigenesis suggests that elafin possesses
tumor-suppressive properties.
Several studies attribute tumor-suppressive properties
to elafin. Recently, we demonstrated that exogenous
elafin expression promoted growth arrest and apoptosis
in breast cancer cell lines [9] and xenograft tumors [10].
In melanoma cell lines and xenografts exogenous elafin
expression also induced apoptotic cell death [27]. As acritical counterbalance against neutrophil elastase (NE)
activity, elafin downregulation may compromise the
epithelial barrier against tumor-promoting NE activity.
High levels of NE are prognostic of poor outcome in breast
cancer patients [28]. The conventionally understood role
of NE in tumor progression is promotion of cell invasion
and metastasis through extracellular matrix degradation
and the cleavage of adhesion molecules [29]. However, NE
knockout severely limited tumor growth and progression
in the loxP-Stop-loxP K-rasG12D mouse model of lung
adenocarcinoma [30], suggesting a role for deregulated NE
activity in early tumorigenesis. Several groups observed the
endocytosis of NE by tumor cells [30,31]. In this context,
NE targeted critical components of intracellular signaling
cascades, including IRS-1 and cyclin E, promoting tumor
growth [30,32]. Pharmacological inhibitors of NE may be
an effective therapeutic modality against tumors that have
lost elafin expression and are therefore more likely to
exhibit deregulated NE activity.
Despite elafin downregulation in the bulk of tumors
examined, we observed that the presence of elafin-positive
tumor cells correlated with poor outcome in both breast
(Figure 3C and D) and ovarian cancer (Figure 5C).
Strikingly, elafin-positive cells were independently prog-
nostic of poor RFS specifically in the IHC-defined luminal
A like breast cancer subtype (Table 1B). Low proliferation
index (Ki67 < 20%) can delineate a subpopulation of
ER-positive tumors approximating the luminal A intrinsic
subtype (that is luminal A-like) [12]. Luminal A tumors
are commonly viewed as the least aggressive breast cancer
subtype. However, long-term (>20 years) follow-up has
revealed that the survival of luminal A patients continued
to decline after 10 years, in contrast other breast cancer
subtypes, which remain relatively stable after 10 years
[11]. Luminal A is proportionally the largest and most
diverse breast cancer subtype and the greatest contributor
to overall breast cancer mortality [22]. Elafin-positive cells
may be a novel biomarker capable of further stratifying
the outcome of ER-positive breast cancer patients.
Notably, elafin expression was consistently associated with
TNBC in our mRNA (Figure S2B), IHC (Figure 3B), and
in vitro (Figure 6A) studies, indicating a role for elafin
expression in this aggressive subtype.
Recently, several studies have also highlighted possible
oncogenic properties of elafin expression. In breast and
ovarian cancer cell lines, exogenous elafin activated the
extracellular signal-regulated kinase (ERK) signaling path-
way independent of its protease inhibitory capacity, which
resulted in increased tumor cell proliferation and migration
[33]. In another study, elafin expression reduced sensitivity
to genotoxic chemotherapeutic agents in ovarian cancer
cell lines [34]. We stably transduced luminal breast cancer
cell lines MCF-7 and T47D cells expressing either
wild-type elafin or elafin M25G, bearing a mutation in the
Ai
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Figure 5 Residual elafin-positive tumor cells are prognostic of poor DSS in patients with stage I/II ovarian cancer. (A) Representative
photomicrographs of elafin immunohistochemical (IHC) staining in invasive ovarian carcinoma demonstrating (i) negative (elafin score = 0) and (ii)
positive (elafin score >0) staining. (B) Frequency distribution illustrating the percentage of cases falling into each categorical score over the range
0 to 8. The dashed line represents the cutoff used in this analysis. (C) Kaplan-Meier survival analysis of overall survival (OS), disease-specific survival
(DSS) and recurrence-free survival (RFS) in elafin-positive and -negative ovarian cancer cases. The top panel represents all the patients, and for the
middle and bottom panels, the patients were grouped into those with stage I/II and III/IV cancer, respectively and subjected to the three different
survival analyses. Significance calculated by rank-sum test.
Caruso et al. Breast Cancer Research  (2014) 16:3417 Page 11 of 14protease inhibitory rendering it incapable of protease
inhibition [24] (Figure 6D). Expression of elafin in the
luminal breast cancer cell lines MCF-7 and T47D
suppressed proliferation independent of the protease
inhibitory domain (Figure 6D). During early tumori-
genesis, elafin downregulation in the bulk of the
tumor may support cell proliferation. A long latency
period between treatment and recurrence is characteristic
of luminal A tumors [11]. Our results demonstrate thatelafin is a marker of luminal A-like tumors likely to recur
(Figure 4B) and decreases cell proliferation in this tumor
cell population (Figure 6D) suggesting that elafin may
play a role in maintaining a dormant cell population
within tumors, which manifest later as recurrence.
Alternatively, elafin could be a biomarker of a quiescent
cell population within luminal A-like tumors. The


























































































































































































































































































































































































































































































Figure 6 Exogenous elafin has growth-suppressive properties in luminal breast cancer cell lines normally lacking elafin expression.
(A) Elafin mRNA expression (Log2 mean-centered values) derived from the Neve et al., 2006 publication of gene expression analysis in 48 breast
cancer cell lines [23] and two HMECs. (B) qPCR analysis of elafin expression by indicated breast cancer cell lines, values normalized to GAPDH and
represented as a ratio to elafin expression in 76NE6 cells. (C) The indicated cell lines were cultured in fresh media for 24 hours, conditioned media
was subject to enzyme-linked immunosorbent assay (ELISA) analysis. A dilution series of recombinant elafin was used as a standard curve to
determine the concentration of elafin in ng/mL of media. (D) MCF-7 and T47D cells were stably transduced with lentivirus containing wild-type
elafin, elafin M25G or green fluorescent protein (GFP). Elafin expression was confirmed by western blot analysis of elafin expression. Actin, loading
control. Each cell line was plated at 5,000 cells per well, cell number was measured at 48, 72, and 96 hours.
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The results presented in this study suggest that elafin is
downregulated during breast and ovarian tumorigenesis,
compared to elafin expression in normal tissue, suggesting
that elafin possesses tumor-suppressive properties. However,
tumors harboring elafin-positive cells, albeit at low
frequency, are aggressive and correlate with poor patientoutcome. Additionally, elafin-positive cells may delineate
a subset of ER-positive breast cancer patients and stage
I/II ovarian cancer patients that would benefit from
more aggressive therapeutic intervention and increased
vigilance. Our in vitro analysis also indicates that elafin
plays a role in growth suppression and may be a factor in
tumor dormancy.
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